Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients
- 472 Downloads
In addition to the effects on glycemic control and body weight, GLP-1 receptor agonists may favorably affect other major cardiovascular disease (CVD) risk factors, although currently available data are still sparse. In this retrospective study, we evaluated the effects of 12-month treatment with liraglutide on major CVD risk factors in 115 type 2 diabetes outpatients (60 men and 55 women), on stable hypoglycemic, anti-hypertensive and/or lipid-lowering therapy.
Clinical and anthropometric data, metabolic and lipid profile, as well as the Visceral Adiposity Index (VAI), an obesity-related CVD risk factor, were measured in all participants at baseline and after 12-month treatment.
Treatment with liraglutide was associated with a significant reduction from baseline values of fasting blood glucose (−42.1 mg/dl, P < 0.05), HbA1c (−1.5 %, −17 mmol/mol, P < 0.05), body weight (−7.1 kg, P < 0.05), waist circumference (-6.8 cm, P < 0.001), total-cholesterol (−27.4 mg/dl, P < 0.05), LDL-cholesterol (−25.4 mg/dl, P < 0.05), triglycerides (−56.1 mg/dl, P < 0.05), and non-HDL-C (−36.6 mg/dl, P < 0.05) and an increase of HDL-cholesterol concentrations (+9.3 mg/dl, P < 0.001), a significant reduction in both systolic and diastolic blood pressure (−14.7 mmHg, P < 0.001 and −9.0 mmHg, P < 0.05, respectively) and a decrease of VAI values (−1.6, P < 0.001). All these differences were independent of changes in BMI and comparable in men and women.
In conclusion, 12-month treatment with liraglutide in add-on to on-going hypoglycemic therapy significantly ameliorates all major CVD risk factors and reduces cardiometabolic risk, as estimated by VAI values.
KeywordsLiraglutide Type 2 diabetes Visceral Adiposity Index Lipids Blood pressure
Type 2 diabetes
Glucagon-like peptide-1 receptor agonists
Visceral Adiposity Index
Conflict of interest
No conflicts of interest exist.
- 7.Marre M, Shaw J, Brändle M et al (2009) LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268–278PubMedCentralPubMedCrossRefGoogle Scholar
- 9.Garber A (2011) Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 13:348–356PubMedCentralPubMedCrossRefGoogle Scholar
- 10.Zinman B, Gerich J, Buse JB et al (2009) LEAD-4 Study investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 32:1224–1230PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Russell-Jones D, Vaag A, Schmitz O et al (2009) Liraglutide effect and action in diabetes 5 (LEAD-5) met + SU study group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 52:2046–2055PubMedCentralPubMedCrossRefGoogle Scholar
- 19.Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA) http://clinicaltrials.gov/show/NCT01147250
- 24.Fonseca V, Madsbad S, Falahati A et al (2009) Once-daily human GLP-1 analog liraglutide reduces systolic BP: a meta-analysis of 6 clinical trials (Abstract). Diabetes 58(Suppl):A146Google Scholar
- 30.Vilsbøll T, Zdravkovic M, Le Thi T et al (2007) Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 30:1608–1610PubMedCrossRefGoogle Scholar